NanoEcho AB

NanoEcho AB is a Swedish medical technology company founded in 2013, based in Lund. The company specializes in developing innovative diagnostic methods to determine if early rectal cancer has spread to nearby lymph nodes. By combining nanotechnology with modern ultrasound imaging, NanoEcho aims to enhance cancer diagnostics, particularly for rectal cancer. The company focuses on improving diagnostic accuracy through high-resolution imaging, collaborating closely with medical professionals in rectal surgery and radiology. Their technology has potential applications in other areas, such as prostate cancer detection and stem cell therapies. NanoEcho operates on a pay-per-treatment business model, targeting market approval in Europe, starting with Sweden, and plans to establish sales through partnerships with distributors and medical technology companies. NanoEcho's shares are publicly traded and registered with Euroclear Sweden AB, ensuring equal rights and voting power for all shareholders.

• Employees 14